Argatroban — HCPCS J0883 (non-ESRD) / J0884 (ESRD on dialysis)

About argatroban FDA label verified May 2026

Argatroban is a synthetic small-molecule direct thrombin inhibitor (DTI) derived from L-arginine. Unlike heparin, which requires antithrombin as a cofactor, argatroban binds reversibly and directly to the active site of thrombin, inhibiting both free and fibrin-bound thrombin. It does not cross-react with heparin antibodies, which is why it is the workhorse anticoagulant for patients with active heparin-induced thrombocytopenia (HIT) or a history of HIT in whom anticoagulation remains necessary.

Originally launched in 2000 as Acova by GlaxoSmithKline (later marketed in the US as Argatra; both brand names are no longer commercially marketed), argatroban is now sold exclusively as generic by multiple manufacturers including Sandoz, Accord Healthcare, Auromedics Pharma, Eagle Pharmaceuticals, Mylan, and others. The multi-source generic landscape is what produced the unusual proliferation of HCPCS codes: each major generic carries its own code pair, billed under the specific manufacturer's J-code — the codes are not therapeutically interchangeable for claims per CMS HCPCS workgroup decisions, even though all products contain identical USP-grade argatroban.

FDA-approved indications are: (1) prophylaxis or treatment of thrombosis in adult and pediatric patients with HIT; and (2) anticoagulation during percutaneous coronary intervention (PCI) in patients who have, or are at risk for, HIT. Argatroban is metabolized hepatically (CYP3A4-independent; primarily by hepatobiliary excretion), giving it a short serum half-life of ~52 minutes in normal hosts and minimal renal clearance — the latter is why it can be used in ESRD without renal dosing adjustment, while bivalirudin (which is 20% renally cleared) often is not.

From a billing perspective, the page focuses on three operational distinctions: (1) the renal-status split between J0883 (non-ESRD) and J0884 (ESRD on dialysis); (2) the manufacturer-specific generic code pairs (J0891/J0892 Accord, J0898/J0899 Auromedics); and (3) the requirement to bill the cumulative milligrams actually infused over the encounter from pump logs — not a scheduled-dose unit count.

The J-code map — renal-status split × manufacturer CMS HCPCS verified May 2026

Six HCPCS codes covering the same molecule. The two-axis grid (renal status × manufacturer family) drives correct selection — CMS treats each pair as a distinct billable product.

Argatroban's HCPCS landscape is unusual because the CMS HCPCS workgroup has chosen to maintain separate codes for: (a) the renal-status of the patient, and (b) the specific manufacturer of the generic product. That produces a six-cell grid. Choosing the wrong cell is the leading source of denials on this drug.

Dosing & aPTT-titrated unit math FDA label verified May 2026

From the FDA-approved argatroban prescribing information (NDA 20-883). All dosing is weight-based and continuously titrated to a coagulation lab.

FDA-labeled dosing regimens

Target-range table — aPTT monitoring & dose-adjust nomogram

Argatroban is not a fixed-dose drug. The FDA label defines a therapeutic aPTT range and instructs clinicians to titrate the infusion to land within it. Most institutions implement this as a written nomogram tied to the infusion order. The labelled nomogram for the HIT indication is summarized below; local nomograms may vary modestly.

Unit math — bill cumulative mg infused, not scheduled doses

Because argatroban is delivered as a continuous IV infusion titrated to lab, there is no "scheduled dose." The billable unit count is the cumulative milligrams actually infused over the encounter, calculated from pump records:

Hepatic-impairment adjustment

Reduce starting infusion to 0.5 mcg/kg/min in any patient with hepatic impairment, ICU heart failure, post-cardiac surgery, or anasarca. Half-life extends to ~181 minutes in moderate-to-severe hepatic impairment, meaning bolus accumulation and prolonged bleeding risk. Hepatic dose reduction is the single most common nomogram error reported in post-market surveillance.

NDC reference FDA NDC Directory verified May 2026

Multi-source generic; NDC depends on the dispensing pharmacy's contract. Confirm pharmacy dispense record before posting the claim.

Administration codes CPT verified May 2026

Argatroban is a therapeutic (non-chemotherapy) IV infusion. For continuous drips spanning hours, bill 96365 as the initial unit + 96366 for each additional hour.

Modifiers CMS verified May 2026

JW / JZ — single-dose vial waste reporting

Per CMS's July 2023 single-dose container policy (CR 12056), one of JZ (no waste) or JW (waste) is required on claims for drugs supplied in single-dose containers when administered from a vial of that type. Whether JZ/JW applies to argatroban depends on the specific product dispensed:

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as argatroban initiation (e.g., hematology consult to confirm HIT). Routine pre-infusion clinical assessment is bundled into the therapeutic infusion admin code.

340B modifiers (JG, TB)

For 340B-acquired argatroban, follow your MAC's current 340B modifier policy. Hospital outpatient departments billing under OPPS are subject to specific 340B reporting requirements; office-based 340B reporting varies by MAC. Argatroban is commonly 340B-eligible at DSH hospitals.

ICD-10-CM FY2026 verified May 2026

HIT is the primary indication and the diagnostic anchor for payer review. Pair with thrombosis codes when present and the long-term anticoagulant Z-code.

Site of care & place of service Verified May 2026

Argatroban is fundamentally an acute-care drug. The overwhelming majority of administrations occur inpatient (ICU/step-down) where the drug is DRG-bundled, with a smaller volume in cardiac cath labs (PCI indication) and a small but meaningful tail in HOPD/observation for stable patients bridging to oral anticoagulation. Outpatient infusion-suite administration is uncommon because aPTT monitoring cadence and bleeding risk usually require inpatient or observation status.

Claim form field mapping CMS verified May 2026

Most argatroban Part B claims are outpatient/observation HOPD on UB-04. Office-based claims (rare) follow CMS-1500.

Payer policy snapshot Reviewed May 2026

Argatroban is on-label first-line for HIT; payers focus on diagnostic substantiation and HCPCS-to-manufacturer match. Outpatient PA is uncommon; inpatient use is covered under MS-DRG.

Off-label / society guidance

The CHEST/ACCP HIT guidelines (2018 update) and the American Society of Hematology 2018 HIT guidelines both list argatroban as a first-line non-heparin anticoagulant for active HIT in patients without significant hepatic impairment. Bivalirudin is a co-equal first-line option in many institutional protocols and is preferred in patients with hepatic impairment. Off-label uses (heparin-line maintenance, peripartum HIT, pediatric outside the labeled population) are generally covered under medical-necessity appeals when supported by guideline language.

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Originator/Sandoz/Eagle line shares J0883/J0884 ASP; Accord and Auromedics have manufacturer-specific codes.

Coverage

No NCD specific to argatroban or to direct thrombin inhibitors. Coverage falls under MAC LCDs for therapeutic IV drug administration and the standard Part B drug coverage framework. All MACs cover argatroban J-codes for FDA-approved indications (HIT and PCI in HIT) with appropriate ICD-10 (D75.82) and clinical documentation.

Code history

• J0883 — permanent code, "Argatroban, 1 mg, for non-ESRD use" (effective with CMS HCPCS reorganization separating non-ESRD vs ESRD use for selected drugs)
• J0884 — permanent code, "Argatroban, 1 mg, for ESRD on dialysis" (paired with J0883)
• J0891 / J0892 — manufacturer-specific Accord Healthcare codes (non-ESRD / ESRD), added to handle ASP segmentation
• J0898 / J0899 — manufacturer-specific Auromedics Pharma codes (non-ESRD / ESRD), similarly added for ASP segmentation

Patient assistance Verified May 2026

Argatroban is generic and acute-care — the patient assistance landscape is much thinner than for branded outpatient drugs. There is no active manufacturer-sponsored patient assistance program (PAP) specifically for argatroban, because the drug is generic and is dispensed almost exclusively in inpatient/HOPD settings where the institution (not the patient) is the immediate payer.

• No manufacturer PAP. The historical brand programs (GlaxoSmithKline Acova access, Mitsubishi Tanabe Argatra access) closed when the products were withdrawn from the US market. Generic manufacturers (Sandoz, Accord, Auromedics, Eagle, Mylan/Viatris) do not run argatroban-specific patient assistance.
• Hospital charity care: for uninsured inpatients, argatroban cost is typically absorbed through the institution's charity care / financial assistance policy — the inpatient is covered under DRG payment for insured patients and through hospital uncompensated care for self-pay.
• Foundation backup (limited): PAN Foundation and HealthWell Foundation generally do not run dedicated HIT or DTI funds. The Anticoagulation Forum patient resources may provide ad-hoc help with bridge-to-warfarin/DOAC outpatient costs.
• 340B-acquired pricing: for DSH/CAH/rural hospitals participating in 340B, argatroban is 340B-eligible at substantial discounts. This is the primary lever for institutional cost mitigation and is invisible to the patient.
• Outpatient bridging to oral anticoagulants (warfarin, DOACs): patient cost concerns at discharge typically shift to the oral agent; argatroban itself is no longer in play once the inpatient/observation course ends.

Common denials & how to fix them Reviewed May 2026

Frequently asked questions

J0883 vs J0884 — when do I use which?

The split is by renal status, NOT payer type. J0883 is for argatroban administered to non-ESRD patients. J0884 is for argatroban administered to patients with end-stage renal disease who are on dialysis. This is a common source of denial: billers sometimes assume J0884 is the "Medicare ESRD bundle" code or that J0883 is the "commercial" code. Both codes carry the same "argatroban, 1 mg" descriptor at the same ASP, but the renal-status distinction must match the chart. Document dialysis status and use the matching code.

Are the generic manufacturer J-codes (J0891/J0892, J0898/J0899) interchangeable with J0883/J0884?

No. Per CMS HCPCS, each manufacturer's argatroban product carries a distinct code pair (non-ESRD / ESRD) and is not therapeutically equivalent for billing. J0883 and J0884 are the originator / multi-source codes; J0891 and J0892 are specific to Accord Healthcare's generic; J0898 and J0899 are specific to Auromedics Pharma's generic. You must bill the product actually dispensed by pharmacy under its specific HCPCS code pair. Switching products mid-encounter requires switching codes. See the J-code map section for the full grid.

Is fondaparinux (Arixtra, J1652) an alternative for HIT?

No — fondaparinux is contraindicated in active HIT per FDA label and CHEST/ACCP HIT guidelines. While fondaparinux does not cross-react with HIT antibodies in vitro and has been used off-label in some case series, the FDA-approved HIT-specific anticoagulants are the direct thrombin inhibitors (argatroban, bivalirudin) and historically the heparinoid danaparoid (no longer marketed in the US). Submitting fondaparinux under a D75.82 HIT diagnosis will trigger payer review and denials in many policies.

How is a continuous IV argatroban drip billed — by scheduled dose or by cumulative mg?

Bill the cumulative milligrams actually infused over the encounter, not a scheduled-dose unit count. Argatroban is delivered as a continuous IV infusion titrated to aPTT, so the only defensible unit count is total mg infused (calculated from pump logs: mcg/kg/min × weight × minutes ÷ 1000). For inpatient claims the drug is generally DRG-bundled; for outpatient and observation encounters the J0883/J0884 (or applicable manufacturer code) line should reflect cumulative infused mg. Billing "one unit per scheduled dose" is a common audit finding.

What is the aPTT target on argatroban?

Per FDA label, titrate the infusion to achieve an aPTT of 1.5 to 3 times the patient's baseline aPTT, not to exceed 100 seconds. Check aPTT 2 hours after initiation and after any dose change. The standard adult initial dose is 2 mcg/kg/min IV continuous infusion (no bolus for the HIT indication); reduce starting dose to 0.5 mcg/kg/min in hepatic impairment, ICU heart failure, post-cardiac surgery, and anasarca. Dose adjustments per institutional nomogram (typical: increase 25–50% if aPTT below target; decrease 25–50% if aPTT above target; hold for aPTT >100 sec and resume at ≥50% lower rate). See target-range table for the full nomogram.

Does argatroban have an antidote?

No specific antidote exists. Argatroban's short serum half-life (~52 minutes in patients with normal hepatic function) provides mitigation — discontinuing the infusion typically restores normal hemostasis within 2–4 hours. In hepatic impairment the half-life extends to ~181 minutes, which is why hepatic dosing reductions are critical. For active bleeding, manage with supportive care (transfusion, surgical hemostasis); recombinant factor VIIa or 4-factor PCC have been used in case reports but are not label-supported reversal agents.

What is the argatroban dose for percutaneous coronary intervention (PCI) in a HIT patient?

Per FDA label for the PCI indication, give an initial bolus of 350 mcg/kg over 3–5 minutes followed by a 25 mcg/kg/min continuous infusion. Activated clotting time (ACT) — not aPTT — is the monitoring lab during PCI; target ACT 300–450 seconds. Additional 150 mcg/kg boluses with infusion rate increases may be required if ACT is below 300 seconds. This dosing differs substantially from the standard 2 mcg/kg/min HIT-prophylaxis/treatment regimen.

Can argatroban be used in pregnancy?

Argatroban is FDA Pregnancy Category B (legacy classification) with limited human data. The FDA label notes no adequate well-controlled studies in pregnant women; use only if clearly needed. For pregnant patients with active HIT, the limited published case-series experience and society guidance (CHEST 2018) supports use when no labeled alternatives exist — coordinate with maternal-fetal medicine and hematology. Document the risk/benefit discussion in the chart for PA support and post-pay audit.

What is the Medicare reimbursement for J0883?

For Q2 2026, the Medicare Part B payment limit for both J0883 and J0884 is $1.013 per mg (ASP + 6%). A 230 mg/24 hr infusion (80 kg patient at 2 mcg/kg/min) reimburses at approximately $232.99 in drug cost (pre-sequestration). Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%. Auromedics product (J0898/J0899) reimburses at $1.376/mg per the same quarter. Accord (J0891/J0892) ASP is not currently published in the public CMS ASP file — verify with the MAC.

Source documents

1. DailyMed — Argatroban injection [Hikma] Prescribing Information
   Representative current FDA label (Hikma, revised May 11, 2026); full dosing, aPTT/ACT targets, hepatic adjustment. Multi-source generic; all argatroban labels on DailyMed.
2. FDA Drugs@FDA — argatroban NDA 20-883 (Acova / Argatra historical)
   Originator FDA approval record; PCI indication added 2002; pediatric dosing added later
3. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
   ASH 2018 HIT guidelines — argatroban as first-line non-heparin anticoagulant; bivalirudin as co-equal option
4. CHEST / ACCP — Treatment and Prevention of Heparin-Induced Thrombocytopenia (Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.) and 2018 update
   Foundational HIT treatment guidelines; argatroban dosing, monitoring, and bridging recommendations
5. CMS — Medicare Part B Drug ASP Pricing File (Q2 2026)
   Quarterly ASP+6% pricing for J0883, J0884, J0898, J0899
6. CMS HCPCS Level II Quarterly Updates
   Quarterly HCPCS bulletins documenting J0883/J0884 renal-status split and J0891/J0892, J0898/J0899 manufacturer-specific code additions and effective dates
7. FDA National Drug Code Directory — argatroban NDCs
   Manufacturer-specific 10/11-digit NDCs for Sandoz, Eagle, Mylan, Accord, Auromedics presentations
8. CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
   Single-dose container drug discard reporting requirements; product label drives applicability
9. CMS — ICD-10-CM (FY2026)
   D75.82 heparin-induced thrombocytopenia; N18.6 ESRD; Z99.2 dialysis dependence
10. UnitedHealthcare — Medical Drug Coverage Policies
    Outpatient drug coverage and notification requirements
11. Aetna Clinical Policy Bulletins — Heparin-Induced Thrombocytopenia (CPB 0451) and related IV therapy CPBs
12. FDA MedWatch / Sentinel Initiative — HIT and DTI biosurveillance reports
    Post-market surveillance for argatroban-associated bleeding and dosing errors

About this page

We maintain this page as a living reference for billers, coders, and pharmacy/RC staff working with argatroban claims. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 23, 2026 — SME audit pass: real DailyMed setid linked (Hikma label revised May 11, 2026), reviewer block updated. Renal-status split (J0883 = non-ESRD vs J0884 = ESRD on dialysis, NOT Medicare vs commercial), 1 mg unit basis, ASP equivalence, and manufacturer-specific generic-code non-interchangeability all verified. No factual corrections required.
• May 22, 2026 — Initial publication. ASP data: Q2 2026. Six HCPCS codes documented (J0883/J0884 originator; J0891/J0892 Accord; J0898/J0899 Auromedics). Wave 7D template adaptation for continuous-infusion-titrated drugs applied (target-range table in #dosing; cumulative-mg unit math emphasis).

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical policy documents. Dosing and aPTT/ACT targets are verified against the FDA prescribing information and the ASH/CHEST HIT guidelines. We do not paraphrase from billing-software vendor blogs.